论文部分内容阅读
[目的]分析GNAS1 T393C多态性与晚期肺癌患者总生存率的相关性。[方法]选取2010年3月至2012年3月94例经病理证实Ⅲ~Ⅳ期接受放疗或化疗的肺癌患者。提取患者全血基因组DNA,应用PCR扩增目的基因片段,Sanger双脱氧测序方法分析GNAS1T393C位点的单核酸多态性基因型。应用SPSS12.0软件COX生存分析临床因素及基因型与晚期肺癌患者生存的相关性。[结果]随访至2012年3月,94例肺癌患者中位生存期14个月,1年、2年总生存率分别为61%和35%。COX生存分析显示GNAS1 T393C三种基因型TT、TC和CC间生存率有统计学差异(OR=0.660,95%CI:0.051~8.568,P=0.039);携带等位基因C的患者生存率明显低于等位基因T携带者(OR=0.333,95%Cl:0.026~4.284,P=0.030)。[结论 ]GNAS1 T393C多态性与肺癌总生存率相关,携带等位基因C的肺癌患者预后更差。
[Objective] To analyze the correlation between the GNAS1 T393C polymorphism and the overall survival rate of patients with advanced lung cancer. [Methods] From March 2010 to March 2012, 94 patients with pathologically confirmed lung cancer who underwent stage Ⅲ ~ Ⅳ radiotherapy or chemotherapy were selected. Genomic DNA was extracted from patients’ whole blood. PCR was used to amplify the target gene fragment. Sanger dideoxy sequencing was used to analyze the single nucleotide polymorphism (SNP) of GNAS1T393C. Clinical application of SPSS12.0 software in COX survival analysis and correlation between genotypes and survival of patients with advanced lung cancer. [Results] The median survival of 94 lung cancer patients was 14 months. The 1-year and 2-year overall survival rates were 61% and 35% respectively. COX survival analysis showed that the survival rates of TT, TC and CC in three genotypes of GNAS1 T393C were statistically different (OR = 0.660, 95% CI: 0.051-8.568, P = 0.039); the survival rate of patients with allele C was significantly Lower than allele T carriers (OR = 0.333, 95% Cl: 0.026-4.284, P = 0.030). [Conclusion] The GNAS1 T393C polymorphism is associated with the overall survival rate of lung cancer, and the prognosis of patients with lung cancer carrying allele C is worse.